Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$0.45.

  • Rocket Pharmaceuticals' EPS (Basic) rose 3661.97% to -$0.45 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.25, marking a year-over-year increase of 1758.24%. This contributed to the annual value of -$2.73 for FY2024, which is 653.55% up from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' EPS (Basic) is -$0.45, which was up 3661.97% from -$0.62 recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year EPS (Basic) high stood at -$0.45 for Q3 2025, and its period low was -$0.89 during Q4 2022.
  • For the 5-year period, Rocket Pharmaceuticals' EPS (Basic) averaged around -$0.7, with its median value being -$0.68 (2021).
  • In the last 5 years, Rocket Pharmaceuticals' EPS (Basic) surged by 3817.9% in 2021 and then plummeted by 5090.91% in 2022.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' EPS (Basic) stood at -$0.68 in 2021, then plummeted by 30.88% to -$0.89 in 2022, then soared by 30.34% to -$0.62 in 2023, then dropped by 2.63% to -$0.64 in 2024, then grew by 29.28% to -$0.45 in 2025.
  • Its EPS (Basic) stands at -$0.45 for Q3 2025, versus -$0.62 for Q2 2025 and -$0.56 for Q1 2025.